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model was developed to perform a cost analysis of OSCHE in patients refractory to 
topical corticosteroids from an employer’s mutual insurance company perspective over 
a one year time horizon. A structured questionnaire was elaborated and answered by 
a Spanish panel of four dermatologists and two occupational physicians, to identify 
therapeutic management and estimate the use of resources associated to OSCHE. The 
clinical information was obtained from published literature and was complemented 
by physicians. The information regarding costs associated to the different types of 
disability was obtained from data of 156 patients from one of the main EMIC in 
Spain. Disabilities are classiﬁed by EMIC in three groups according to the time spent 
on sick leave: Partial disability (3 months), partial permanent disability (24 months) 
and total permanent disability (limited to current profession). RESULTS: Annual total 
costs of OSCHE for a Spanish EMIC were on average over a60,000 per patient. Direct 
costs represented 1.4% and indirect costs 98.6% of total costs. Total permanent dis-
ability was the most important cost driver, representing 69.3% of total costs, although 
only 18% of patients were estimated to reach this type of disability. CONCLUSIONS: 
Disability is the most important predictor of total costs in patients with OSCHE for 
the EMIC in Spain. Indirect costs are by far the most important cost driver (98.6%) 
for this disease. An effective therapy for OSCHE may signiﬁcantly reduce the number 
of disabilities and therefore indirect costs.
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OBJECTIVES: To estimate the total costs of moderate to severe psoriasis patients in 
Spain. METHODS: An observational study was conducted at 123 centers in Spain 
recruiting 1217 patients (60.8% males, mean age 45.1 o 13.9 years, 95.6% with active 
treatment) with moderate (60.8%) to severe (39.2%) psoriasis (VACAP study). Direct 
and indirect resource consumption during the study was collected for every patient 
using patient notebooks. Direct resource use consisted in inpatient hospitalization, 
surgeries, emergency room visits, consultations (primary and secondary care, nursery, 
other health care professionals and alternative medicine visits), laboratory and diag-
nostic tests, medication (prescription and non-prescription drugs paid by patients), 
and phototherapy sessions. Indirect costs included productivity losses (full or part-
time), social assistance and out-of-pocket expenses paid directly by patients (travel 
costs, formal caregivers). Resource use unitary costs were obtained from e-Salud 
database. Four-month costs were extrapolated to annual costs (a, year 2009 values). 
RESULTS: Mean annual total cost per patient was a6881 (95% conﬁdence interval 
[CI], a5365–a8370). Direct and indirect costs accounted for a6420 (95%CI, a5067–
a7745) and a461 (95%CI, a299–a625) representing 93.3% and 6.7% of total esti-
mated costs respectively. The most important categories of direct costs were 
prescription medication (a3667, 95%CI, a2954–a4381, 53.3% of direct costs), pho-
totherapy sessions (a1405, 95%CI, a1144–a1666, 20.4%), consultations (a517, 
95%CI, a434–a567, 7.5%) and hospital day visits (a436, 95%CI, a294–a578, 6.3%) 
The most signiﬁcant indirect costs were loss of productivity (a357, 95%CI, a216–
a500, 77.5% of indirect costs) and travel costs (a85, 95%CI, a76–a95, 18.5%). 
CONCLUSIONS: In Spain, mean annual cost per patient with moderate to severe 
psoriasis represents a6881, of which 93% were direct costs and 7% indirect costs.
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OBJECTIVES: This study estimated the economic consequences of topical moxiﬂoxa-
cin compared with topical oﬂoxacin in the treatment of acute infectious conjunctivitis 
in Scotland (SC), Spain (ES) and The Netherlands(NL). METHODS: The rates of 
treatment failure, deﬁned as no improvement or worsening symptoms, were estimated 
by a meta-analysis of randomized controlled trials (RCT) of moxiﬂoxacin. The 
resources consumed and costs of treatment failure were assessed by a survey of 39 
General Practitioners (GP) and 14 Ophthalmologists (OPH). National databases were 
used to estimate resource costs. The potential economic beneﬁt was estimated, and 
sensitivity analyses were performed using moxiﬂoxacin’s failure rate advantage from 
trials directly comparing the drugs and meta-analysis of patients with conﬁrmed bacte-
rial infection (from 3.3% to 6.5% lower). RESULTS: Treatment failure costs are 
driven by extra physician consultations,and bacterial cultures. The average cost of a 
treatment failure in ES, SC and NL respectively is a38, a72, a53 when managed by a 
GP compared to OPH estimates of a108, a133, and a215. OPH extremes were a93 
to a279a. Assuming 1.5% of the population experiences acute infectious conjunctivitis 
and a 10% failure rate in symptomatic improvement in control group patients, the 
estimated annual cost of failure ranges from a57,000a to a322,500 per million inhabit-
ants. Primarily OPH use the studied drugs. With 4.7% less treatment failure when 
moxiﬂoxacin instead of oﬂoxacin is used by OPH, the economic beneﬁt was estimated 
at a5.1, a6.3, a10.13 per patient in ES, SC and NL respectively. This is a cost saving 
of approximately 11% on specialist treatment independent of the country. Sensitivity 
analysis resulted in an economic beneﬁt from a3.58 to a14.01 as extremes of all 
countries. CONCLUSIONS: The decrease of treatment failure rate using moxiﬂoxacin 
instead of oﬂoxacin in acute infectious conjunctivitis provides an economic beneﬁt in 
three countries of interest.
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OBJECTIVES: Acute otitis media (AOM) is the most common childhood infection 
next to common cold. The impacts of AOM deserve attentions from both public health 
and economic perspectives. Taiwan’s National Healthcare Insurance (NHI) provides 
comprehensive coverage and to date, over 97% of the populations are insured. In this 
study we use the NHI claim database to evaluate the economic impacts of AOM. 
METHODS: We reviewed the claims of pediatric patients with AOM who had 
received treatment during January 1–December 31, 2006. Numbers of visits and 
expenses (in $New Taiwan Dollars, exchange rate with $USD 32^33.5 during year 
2006) were calculated. The data size is around 400 gigabytes. RESULTS: The mean 
age of disease was 5.4 years-old. With 29.6 % under 3 years-old, 48.1% under 7 
years, and 22.3 % under 12 years-old. The male: female ratio was: 1.2:1. There were 
733,546 visits related to the occurrence of AOM, 717,263 (visits) occurred in outpa-
tient settings; 16,283 admissions were related to AOM care. A total of 45.8% 
(328,517 out of 717,263 visits) were treated by pediatricians, 35.2% (252,347 visits) 
were treated by otolaryngologists, and 4.6% (34,840 visits) were treated by family 
practitioners. Around 97.0% (15,799 out of 16,283 admissions) were under pediatric 
and 1.7% (281) were under otolaryngology services. The total annual expenses related 
to AOM care was 554,507,868 $NTD, comprising of 315,671,421 $NTD in outpa-
tient (56.9%), and 238,836,447 $NTD in inpatient cares (43.1%). In average, AOM 
took 3.6 antibiotics-days, and 4.5 admission-days to treat. CONCLUSIONS: Over 
half of the AOM care expenses were spent in ambulatory services. Pediatricians took 
46% outpatient and 97% inpatient AOM care resources. The nation-wide economic 
impact of AOM was around 0.55 billion $NTD annually. The NHI claim database 
provides possibility for further economic analysis.
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OBJECTIVES: To compare the cost of cataract surgery in patients with and without 
astigmatism, as reported in the French national Diagnosis Related Group (DRG) 
database (PMSI: Programme de Médicalisation des Systèmes d’Information). 
METHODS: The 2007 DRG database was used. Patients with cataract surgery were 
identiﬁed by the surgery procedure codes (BFGA001-BFGA010; BFLA001-BFLA004). 
Patients with declared astigmatism had a H522 ICD10 code. DRG standard cost was 
adjusted according to the number of procedures. Surgery and anaesthesia costs esti-
mated from the Echelle National des Coûts were adjusted with the same method. 
Average costs were calculated in both groups. Student t-test and chi-square were used 
to compare the two groups. RESULTS: A total of 475 declared astigmatic and 579,778 
without declared astigmatism patients were extracted (age: 73.6 years, 2 males: 3 
females). Astigmatic patients were more often operated on in a private hospital. 
Astigmatic patients showed a trend towards a longer length of stay (2.41 versus 2.17 
days; p  0.12, ambulatory patients excluded), more co-morbidity (2.38 versus 1.03; 
P  0.001) and more procedures (3.03 versus 2.43; P  0.001). The cost of procedures 
was higher for astigmatic patient (a580 versus a464) leading to a higher total hospital 
cost (a1488 versus a1372). CONCLUSIONS: Astigmatism is dramatically under-
reported in the PMSI database in comparison to nationwide prevalence rate estimates. 
Astigmatic patients required more procedures, partially due to increased co-morbidity. 
An astigmatic patient costs more and this is not taken into account by today’s V11 
clustering cost algorithm. Time and motion analysis should be conducted to better 
understand astigmatism management during cataract surgery.
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OBJECTIVES: Psoriasis is a chronic disease with signiﬁcant psychosocial morbidity 
and lower health-related quality of life (QoL). In Sweden, an estimated 250,000 
persons or nearly 3% of the population have psoriasis. There are few studies on the 
total cost of psoriasis therapy, especially studies that take both direct and indirect 
costs into account. The aim of the present study was to analyse and estimate health 
related QoL and costs of psoriasis during a year in relation to disease severity among 
psoriasis patients, based on patient populations from two dermatology centres in 
Sweden. METHODS: The study is based on data from three sources; a patient survey, 
a retrospective chart review, and data from a drug registry. Information about Qol 
